Corbus Pharmaceuticals Holdings (CRBP) EPS (Weighted Average and Diluted) (2018 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly EPS (Weighted Average and Diluted) of -$1.9 in Q3 2025, down 31.94% quarter-over-quarter from -$1.44 in Q2 2025, and down 65.22% on a YoY basis from -$5.46 in Q3 2024.
Corbus Pharmaceuticals Holdings (CRBP) EPS (Weighted Average and Diluted) (2018 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' EPS (Weighted Average and Diluted) history runs 8 years deep, the most recent figure standing at -$1.9 for Q3 2025.
- In Q3 2025, EPS (Weighted Average and Diluted) fell 65.22% year-over-year to -$1.9; the TTM figure through Sep 2025 stood at -$5.49 (down 17.56% YoY), while the FY2024 annual figure was -$3.68, up 64.31% from the prior year.
- EPS (Weighted Average and Diluted) was -$1.9 for Q3 2025 at Corbus Pharmaceuticals Holdings, down from -$1.44 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.02 in Q3 2021 to a low of -$10.86 in Q4 2021.
- Historically, EPS (Weighted Average and Diluted) has averaged -$2.34 across 5 years, with a median of -$1.9 in 2025.
- The sharpest annual moves came in 2022 and 2024: EPS (Weighted Average and Diluted) plunged 10450.0% in 2022, then jumped 80.42% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$10.86 in 2021, then jumped by 76.06% to -$2.6 in 2022, then jumped by 31.15% to -$1.79 in 2023, then jumped by 57.54% to -$0.76 in 2024, then sank by 150.0% to -$1.9 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.9 (Q3 2025), -$1.44 (Q2 2025), and -$1.39 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Corbus Pharmaceuticals Holdings | 133.67 Mn | 105.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.90 |
| Jun 30, 2025 | -1.44 |
| Mar 31, 2025 | -1.39 |
| Dec 31, 2024 | -0.76 |
| Sep 30, 2024 | -1.15 |
| Jun 30, 2024 | -0.90 |
| Mar 31, 2024 | -0.83 |
| Dec 31, 2023 | -1.79 |
| Sep 30, 2023 | -2.27 |
| Jun 30, 2023 | -2.05 |
| Mar 31, 2023 | -4.24 |
| Dec 31, 2022 | -2.60 |
| Sep 30, 2022 | -2.11 |
| Jun 30, 2022 | -3.18 |
| Mar 31, 2022 | -2.26 |
| Dec 31, 2021 | -10.86 |
| Sep 30, 2021 | -0.02 |
| Jun 30, 2020 | -0.52 |
| Jun 30, 2019 | 0.03 |
| Jun 30, 2018 | -0.21 |